Table 1. Patient characteristics.
| Variable | Goserelin (n=59) | Triptorelin (n=44) | Leuprolide (n=22) | p-value |
|---|---|---|---|---|
| Age (y) | 76.2±6.8 | 75.0±6.8 | 77.5±8.4 | 0.539 |
| Body mass index (kg/m2) | 23.3±3.5 | 22.4±3.3 | 23.8±3.5 | 0.607 |
| PSA before castration (ng/mL) | 123.3±205.5 | 193.4±324.9 | 90.4±164.2 | 0.169 |
| Testosterone before castration (ng/mL) | 4.3±1.1 | 4.1±1.2 | 4.7±1.5 | 0.079 |
| Prostate volume (mL) | 54.7±31.3 | 42.0±17.4 | 52.1±38.8 | 0.728 |
| Gleason score | 0.504 | |||
| ≤6 | 9 (15.3) | 3 (6.8) | 3 (13.6) | |
| 7 | 11 (18.6) | 5 (11.4) | 3 (13.6) | |
| ≥8 | 39 (66.1) | 36 (81.8) | 16 (72.7) | |
| Distant metastasis | 54 (91.5) | 39 (88.6) | 19 (86.4) | 0.248 |
| Patients with MAB | 33 (55.9) | 25 (56.8) | 4 (18.2) | 0.005 |
Values are presented as mean±standard deviation or number (%).
PSA, prostate-specific antigen; MAB, maximal androgen blockade.